


ADC DEVELOPMENT FROM DISCOVERY TO CLINICS

THE TNO TRISKELION BIOANALYTICAL APPROACH



TNO TRISKELION BV


When you look for a trusted independent research partner who can offer full support in assessing the safety and efficacy of your products, TNO Triskelion offers a complete portfolio of high quality and innovative services with over 35 years of experience. We operate in compliance with the highest quality standards, including GLP, ISO17025 and AAALAC. TNO Triskelion has a track-record of conducting tailor-made studies by integrating expert knowledge and flexibility to meet your schedules.

The complex structure of antibody-drug conjugates (ADCs) and their different drug-to-antibody ratios (DARs) make bioanalytical assessment challenging. In order to address all aspects of ADCs, TNO Triskelion combines the latest ligand-binding assays (LBAs) and mass spectrometry (MS) platforms to measure your ADC in biological matrices.

We measure the most common analytes, such as the total amount of conjugated antibodies and antibodies, the released and/or free drug, DAR distribution and anti-drug antibodies (ADAs). Our recommendations are illustrated on the reverse. All assays can be validated according to the latest FDA/EMA guidelines on Bioanalytical Method Validation.

ADC DEVELOPMENT FROM DISCOVERY TO CLINICS

THE TNO TRISKELION BIOANALYTICAL APPROACH



tnotriskelion.com

For more information, please contact us.

Visiting address
Utrechtseweg 48
3704 HE Zeist
The Netherlands

The Netherlands
P +31 88 866 16 20
F +31 88 866 69 70
pharma@tno.triskelion.nl

Postal address
P.O. Box 844
3700 AV Zeist
The Netherlands

a **TNO** company